Streetbeat News

Stock Prices

MMM

Analysts have provided a range of ratings for 3M (NYSE:MMM) over the past three months, with a mix of bullish, somewhat bullish, indifferent, and somewhat bearish sentiments. The average 12-month price target has increased to $107.29, reflecting a 4.95% rise from the previous average. Key analysts have adjusted their ratings and price targets, indicating varied expectations for 3M's future performance. Despite a slight decline in revenue growth, 3M maintains strong profitability and financial health, though it faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 12:01 pm

LDOS

Leidos has received a $738 million follow-on contract from the US Air Force, which is expected to enhance its revenue and market position.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 12:01 pm

SONN

Sonnet BioTherapeutics has announced the generation and in vitro characterization of two novel drug candidates, SON-1411 and SON-1400. These candidates are based on a modified version of Interleukin-18 (IL-18BPR) and have shown promising bioactivity in receptor binding assays. SON-1411 is manufactured in CHO cells, while SON-1400 is made in E. coli. Both drugs could have broad applications in oncology and cell-based therapies.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 12:01 pm

CARA

Cara Therapeutics (NASDAQ:CARA) has been analyzed by 5 analysts in the last three months, showing a range of bullish to bearish perspectives. The average 12-month price target is $4.72, with a high of $5.00 and a low of $3.60. The company's market capitalization is strong, but it faces challenges with revenue growth, net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 12:01 pm

GTHX

In the last three months, 8 analysts have published ratings on G1 Therapeutics (NASDAQ:GTHX), all of which are bullish. The average 12-month price target is $10.88, with a high of $12.00 and a low of $9.00. The company's financial health shows mixed results, with strong revenue growth but challenges in debt management and return on equity.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 12:00 pm

EPAM

EPAM Systems (NYSE:EPAM) has received a range of analyst ratings over the past three months, with a notable decrease in the average 12-month price target by 14.51%. Analysts have predominantly lowered their price targets and ratings, reflecting a negative shift in sentiment. Despite challenges such as a 3.76% decline in revenue growth, EPAM maintains strong profitability metrics, including a net margin of 9.97% and a low debt-to-equity ratio of 0.05.

Portfolio Pulse from Benzinga Insights

June 13, 2024 | 12:00 pm

R

Ryder has announced an increase in its long-term adjusted return on equity (ROE) target to a range of 20% - 22% over the cycle, up from the previous target of 17% - 19%, during its 2024 Investor Day.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:56 am

JILL

J. Jill shares are trading lower after the company announced the pricing of a public offering of 2 million common stock at $31 per share.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:52 am

TSLA

Tesla Inc. (NASDAQ:TSLA) has announced that it will increase the price of its Model 3 sedan in the European Union starting July 1, 2024, due to new import tariffs on cars made in China. The company is urging customers to take delivery in June to secure the current price.

Portfolio Pulse from Anan Ashraf

June 13, 2024 | 11:46 am

AVGO

GME

QQQ

SPY

TSLA

Wall Street is poised to extend its record run, driven by tech strength. Broadcom and Tesla are leading the charge, with Broadcom reacting to earnings and a stock split, and Tesla on the likelihood of shareholders approving Elon Musk’s pay package. GameStop also rebounds. Key economic data releases include the producer price inflation report and weekly jobless claims.

Portfolio Pulse from Shanthi Rexaline

June 13, 2024 | 11:45 am